<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907437</url>
  </required_header>
  <id_info>
    <org_study_id>519</org_study_id>
    <nct_id>NCT02907437</nct_id>
  </id_info>
  <brief_title>Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia</brief_title>
  <official_title>Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients: A Double- Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beer Yaakov – Ness Ziona Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bar-Ilan University, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beer Yaakov – Ness Ziona Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current medications have only a limited effect on two core symptoms of schizophrenia,
      negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline
      which has a beneficial effect in various neurological disorders. In the past years, various
      findings from clinical studies showed its potential role for the treatment of these symptoms
      of schizophrenia. The current study aims to examine the efficacy of minocycline as add-on
      treatment for alleviating positive, negative and cognitive symptoms in schizophrenia
      patients.The current study is a single center, double-blind, randomized study that assess the
      adjuvant therapeutic effect of minocycline vs. placebo added to antipsychotic medications, in
      adult patients suffering from schizophrenia. Patients will be recruited and randomly
      allocated to a minocycline or placebo treatment (200 mg/day) for 6 weeks of treatment. In
      addition, all patients will receive probiotics (450mg/day) in order to prevent any
      gastrointestinal influences of antibiotics administration. Positive and negative symptoms ,
      as well as cognitive functions will be assessed before and after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Change in PANSS scores over the 6-weeks study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>Change in SANS scores over the 6-weeks study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI)</measure>
    <time_frame>Change in CGI scores over the 6-weeks study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment (MoCa) task</measure>
    <time_frame>Change in MoCa scores over the 6-weeks study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail making task (TMT)</measure>
    <time_frame>Change in TMT scores over the 6-weeks study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empathy Cartoon task</measure>
    <time_frame>Change in Empathy Cartoon task scores over the 6-weeks study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpersonal Reactivity Index (IRI) Questionnaire</measure>
    <time_frame>Change in IRI scores over the 6-weeks study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Minocycline treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Minocycline (200 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Intervention: Drug: Placebo (200 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline as an add-on drug (200 mg/day)</description>
    <arm_group_label>Minocycline treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(200 mg/day)</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>(450 mg/day)</description>
    <arm_group_label>Minocycline treatment</arm_group_label>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 18-60 years of age.

          2. Diagnostic and Statistical Manual (DSM) 5 diagnosis of Schizophrenia/ Schizo effective
             disorder based on the Structured Clinical Interview for the Diagnostic and Statistical
             Manual for Mental Disorders (SCID) for schizophrenia and confirmed by two senior
             psychiatrists.

          3. Initiated on treatment with stable dosage (within +/- 25%) of atypical anti-psychotic
             medication for at least 6 weeks.

          4. Capable and willing to provide informed consent.

          5. Able to adhere to the treatment schedule.

          6. Able to read, hear, write and speak the local language.

          7. Has signed a written informed consent to participate in the study.

        Exclusion Criteria:

          1. Patients with acute, unstable, or decompensated medical condition.

          2. Present substance abuse.

          3. Major depression (MDD) diagnosis.

          4. Attention deficit/ hyperactivity disorder (ADHD/ADD) diagnosis.

          5. Cognitive dysfunction, such as Alzheimer disease or retardation.

          6. Acute psychotic state.

          7. Aggressive or violent patient or with vast history of aggressive or violent behavior.

          8. Diagnosis of Borderline/ Anti Social/ Narcissistic personality disorders.

          9. Previous sensitivity to Minocycline.

         10. Current suicidal ideation or history of a suicide attempt in the past three years

         11. Known or suspected pregnancy or women of childbearing potential not using a medically
             accepted form of contraception .(if using oral contraceptives, during the Minocycline
             treatment, subject should use an additional contraceptives), or women who are
             breastfeeding.

         12. Subjects who are taking a known contraindication to Minocycline treatment
             (anti-coagulants, other antibiotics (of the penicillin group), methoxyflurane,
             Isotretinoin).

         13. Subjects who had received treatment with Minocycline or β-lactam antibiotics in the
             preceding half year before study entry.

         14. Subjects who are under compulsory hospitalization.

         15. Subjects with medical history of Intestinal disease, Peptic ulcer or gastritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Stryjer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beer Yaakov – Ness Ziona Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafael Stryjer, MD</last_name>
    <phone>+528612945</phone>
    <email>rafael.stryjer@beerness.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Netali Mor, MA</last_name>
    <phone>+972524207260</phone>
    <email>netalimor@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bees Yaakov and Ness Ziona Mental Health Center</name>
      <address>
        <city>Beer Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Stryjer, MD</last_name>
      <phone>+972528612945</phone>
      <email>rafael.stryjer@beerness.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Netali Mor, MA</last_name>
      <phone>+972524207260</phone>
      <email>netalimor@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 Sep;26(9):1185-93. doi: 10.1177/0269881112444941. Epub 2012 Apr 23.</citation>
    <PMID>22526685</PMID>
  </reference>
  <reference>
    <citation>Chaves C, de Marque CR, Wichert-Ana L, Maia-de-Oliveira JP, Itikawa EN, Crippa JA, Zuardi AW, Todd KG, Baker GB, Dursun SM, Hallak JE. Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):550-2. doi: 10.1016/j.pnpbp.2010.01.020. Epub 2010 Feb 6.</citation>
    <PMID>20138948</PMID>
  </reference>
  <reference>
    <citation>Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014 May;24(5):788-99. doi: 10.1016/j.euroneuro.2013.10.010. Epub 2013 Nov 4. Review.</citation>
    <PMID>24252823</PMID>
  </reference>
  <reference>
    <citation>Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012 May 1;26(5):391-401. doi: 10.2165/11632000-000000000-00000. Review.</citation>
    <PMID>22486246</PMID>
  </reference>
  <reference>
    <citation>Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci. 2013 Winter;25(1):E06-7. doi: 10.1176/appi.neuropsych.11120376.</citation>
    <PMID>23487204</PMID>
  </reference>
  <reference>
    <citation>Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014 Mar 30;215(3):540-6. doi: 10.1016/j.psychres.2013.12.051. Epub 2014 Jan 9.</citation>
    <PMID>24480077</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 Feb;71(2):138-49. doi: 10.4088/JCP.08m04666yel. Epub 2009 Nov 3.</citation>
    <PMID>19895780</PMID>
  </reference>
  <reference>
    <citation>Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65. Review.</citation>
    <PMID>19579286</PMID>
  </reference>
  <reference>
    <citation>Lisiecka DM, Suckling J, Barnes TR, Chaudhry IB, Dazzan P, Husain N, Jones PB, Joyce EM, Lawrie SM, Upthegrove R, Deakin B. The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. Trials. 2015 Mar 2;16:71. doi: 10.1186/s13063-015-0580-x.</citation>
    <PMID>25886254</PMID>
  </reference>
  <reference>
    <citation>Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011 Oct;132(1):96-110. doi: 10.1016/j.pharmthera.2011.06.003. Epub 2011 Jun 15.</citation>
    <PMID>21704074</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beer Yaakov – Ness Ziona Mental Health Center</investigator_affiliation>
    <investigator_full_name>Dr. Stryjer Rafael (MD)</investigator_full_name>
    <investigator_title>Senior Psychatrist</investigator_title>
  </responsible_party>
  <keyword>Minocycline</keyword>
  <keyword>Negative symptoms</keyword>
  <keyword>Cognitive symptoms</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

